| Product NDC: | 68289-008 |
| Proprietary Name: | Cephalexin |
| Non Proprietary Name: | Cephalexin |
| Active Ingredient(s): | 125 mg/5mL & nbsp; Cephalexin |
| Administration Route(s): | ORAL |
| Dosage Form(s): | SUSPENSION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 68289-008 |
| Labeler Name: | Jazeera Pharmaceutical |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA065444 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20090901 |
| Package NDC: | 68289-008-01 |
| Package Description: | 100 mL in 1 BOTTLE (68289-008-01) |
| NDC Code | 68289-008-01 |
| Proprietary Name | Cephalexin |
| Package Description | 100 mL in 1 BOTTLE (68289-008-01) |
| Product NDC | 68289-008 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Cephalexin |
| Dosage Form Name | SUSPENSION |
| Route Name | ORAL |
| Start Marketing Date | 20090901 |
| Marketing Category Name | ANDA |
| Labeler Name | Jazeera Pharmaceutical |
| Substance Name | CEPHALEXIN ANHYDROUS |
| Strength Number | 125 |
| Strength Unit | mg/5mL |
| Pharmaceutical Classes | Cephalosporin Antibacterial [EPC],Cephalosporins [Chemical/Ingredient] |